SCHEMBL3400844

SCHEMBL3400844

COc1cc(N2CCOCC2)ccc1Nc1cc(Nc2ccccc2C(=O)O)c(Cl)cn1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 9/20 0.85
MAPK9 P45984 6/20 0.85
PTK2 Q05397 6/20 0.66
MAPK8 P45983 2/20 0.64
INSR P06213 3/20 0.64
ALK Q9UM73 3/20 0.64
LRRK2 Q5S007 3/20 0.64
EGFR P00533 2/20 0.64
IGF1R P08069 2/20 0.64
CDC7 O00311 1/20 0.64
PLK4 O00444 1/20 0.64
CHEK1 O14757 1/20 0.64
AURKA O14965 1/20 0.64
DCLK1 O15075 1/20 0.64
PDPK1 O15530 1/20 0.64
DAPK3 O43293 1/20 0.64
DYRK3 O43781 1/20 0.64
JAK2 O60674 1/20 0.64
PRKD3 O94806 1/20 0.64
PAK4 O96013 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1232888 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL3775588 0.91 MAPK10 (0.86) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL3767760 0.90 MAPK10 (0.80) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL3781239 0.90 MAPK10 (0.79) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL375436 0.86 MAPK9 (0.86) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL12886390 0.84 MAPK10 (0.70) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL12887670 0.83 MAPK10 (0.85) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL4554864 0.83 MAPK10 (0.69) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL4554865 0.83 MAPK10 (0.69) MAPK10MAPK9PTK2MAPK8INSR
SCHEMBL3433621 0.83 MAPK10 (0.68) MAPK10MAPK9PTK2MAPK8INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
EP-2249650-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GlaxoSmithKline LLC (US) 2010-11-17 EP disclosed
WO-2009105498-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 WO disclosed
WO-2009105498-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK PTK2, JAK2, SRC MAPK10 386/4885MAPK9 173/4885PTK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.